AstraZeneca is one of the leading pharmaceutical companies and number 1 in clinical trials in Austria
AstraZeneca is an essential partner in the Austrian healthcare system.
AstraZeneca is one of the leading pharmaceutical companies and number 1 in clinical trials in Austria
Top-10 companies for ongoing clinical studies in Austria*
2025
Top-15 companies for revenues in hospital + retail market in Austria
(€ mill.), 2024
Ongoing clinical trials of the top-15 companies in hospital + retail market in Austria
(number), 2025*
* Listing of all active studies with start dates from January 1, 2022, to April 30, 2025 (Source: Trialtrove, as of April 30, 2025; https://clinicalintelligence.citeline.com/trials/dashboard?qId=8355ede8-f8b6-4f6d-809b-be9d10195e10)
Leader in clinical trials in oncology
Top-5 companies for ongoing lung cancer clinical studies in Austria
(number), 2025
Top-5 companies for ongoing breast cancer clinical studies in Austria
(number), 2025
We are particularly proud that we are able to cover a broad therapeutic spectrum with our clinical trials in Austria: as such, we have active studies in all four of AstraZeneca’s therapeutic areas – Oncology, CVRM, RIV, and Rare Disease (through our subsidiary Alexion).
Clinical studies
by therapeutic area
Every Euro invested in clinical trials by the pharmaceutical industry generates €1.95 for the Austrian economy.
The performance of clinical trials by the pharmaceutical industry leads – in addition to the benefit for patients – to positive macroeconomic effects.
AstraZeneca’s investment in clinical trials translates into benefits for the healthcare system in terms of financial savings, targeting and improving treatment as well as the access to new drugs.
Every Euro invested in clinical trials by the pharmaceutical industry generates €1.95 for the Austrian economy.
The performance of clinical trials by the pharmaceutical industry leads – in addition to the benefit for patients – to positive macroeconomic effects.
Thanks to this leverage effect, the €2.8 million invested in 2023 translates into €5.5 million of expected benefits for the Austrian healthcare system.
Clinical trials bring benefits for patients, the healthcare system, research, and the economy
Sources: The European House – Ambrosetti elaboration of AstraZeneca Österreich, 2023. Updated 2025. | Trialtrove, as of April 30, 2025; https://clinicalintelligence.citeline.com/trials/dashboard?qId=8355ede8-f8b6-4f6d-809b-be9d10195e10